• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Illinois Biotechnology Industry Organization adds to board of directors

Illinois Biotechnology Industry Organization adds to board of directors

December 11, 2014
CenterWatch Staff

The Illinois Biotechnology Industry Organization (iBIO) has elected several new additions to its board of directors. The new board members include Daniel Brennan of Lundbeck U.S., Jamie Oldani of Eli Lilly, Susanne Resatz of Vetter Development Services USA and Geeta Vemuri of Baxter Ventures.

Brennan is vice president and general manager of neurology and business development for Lundbeck U.S. The neurology business unit is responsible for commercializing several products, including Xenazine (tetrabenazine, Huntington disease), Sabril (vigabatrin, refractory partial complex seizures), Onfi (clobazam, Lennox-Gastaut disease) and Northera (droxidopa, neurogenic orthostatic hypotension as a result of neurological disorders and other means).

Oldani is the midwest director of State Government Affairs for Eli Lilly. The global pharmaceutical research-based company, headquartered in Indianapolis, Ind., has a heritage more than 135 years strong, with approximately 39,000 employees worldwide. Oldani represents the company in public, private and professional forums addressing policy issues involving the healthcare industry. She is responsible for monitoring the legislative, regulatory, administrative and political processes that affect government funded healthcare programs, as well as their impact upon industry.

Resatz, Ph.D., president of Vetter Development Services USA, heads Vetter’s clinical manufacturing facility in suburban Chicago, Ill. Vetter is an independent international contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany. Its Chicago facility is the company’s first U.S. site, and provides development support and aseptic manufacturing for preclinical through phase IIb injectables, primarily complex biologics.

Vemuri joined Baxter in January 2012 as vice president, head of Baxter Ventures, the corporation's $200 million venture fund. Previously, she was a general partner at Quaker Partners, where she led investments in biopharmaceutical and healthcare companies and was an integral part of the team raising capital for the funds. Vemuri's role in building and mentoring portfolio companies has facilitated successful exits through acquisitions and Initial Public Offerings.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing